SENSUS HEALTHCARE, INC.
| Revenue | $17.5M |
|---|---|
| Operating income | $-7.5M |
| Net income | $-11.4M |
| Free cash flow | $-6.9M |
| Operating margin | -43.1% |
| Net margin | -65.0% |
| Return on equity | -30.9% |
| Period | TTM 2026-06-30 |
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
wait rather than buy aggressively.
Q2 revenue fell 68.5% to $2.3 million on just 11 units, while adjusted EBITDA worsened to negative $3.0 million; management attributes much of the miss to eight units delayed by financing and expects 20-plus units in both Q3 and Q4. The bull case is improving reimbursement-driven demand, broader customers, and recurring revenue, but the bear case is that pipeline conversion remains unproven, cash fell to $15.2 million, inventory rose to $18.4 million, and the historically largest customer is not expected to return.
- Q2 2026 Results
- Financing Delay
- Unit Volume Recovery
- Fair Deal Agreement
- Sensus Link
- Customer Concentration
Near term
Q3 execution is the key catalyst: eight delayed SRT-100 units were approved and sold, with an expected average selling price near $250,000 each.
Management explicitly expects at least 20 units in Q3 and Q4; failure to reach that threshold would undermine the recovery narrative.
Gross margin may remain pressured by international mix and upfront costs from Fair Deal placements, even if unit volume rebounds.
Cash declined by $3.1 million sequentially while adjusted EBITDA was negative $3.0 million, increasing the importance of near-term conversion and cash discipline.
Longer term
Recurring revenue could improve predictability if Fair Deal and rental utilization scales; management said the pipeline is approximately 50% recurring models versus direct purchases.
Sensus Link has nearly universal adoption among new customers and could add high-margin monthly revenue, but expansion across the installed base is still early and unquantified.
Larger physician groups and healthcare systems could create multi-location leverage, though these sales cycles are longer and no contract wins or revenue contribution were disclosed.
The loss of the historically largest customer increases the need to prove that a broader customer base can replace concentrated demand.
Australia and the broader Asia-Pacific region offer expansion potential, but the call provided interest and market statistics rather than quantified orders or a clear profitability timeline.
Red flags
The financing explanation is plausible for the timing issue, but it also exposes dependence on third-party approvals; management provided no evidence that the replacement financing process is structurally more reliable.
Management repeatedly described a stronger pipeline and commercial momentum without quantifying pipeline value, conversion rates, backlog, or signed orders beyond the eight delayed units.
The company posted a $3.0 million adjusted EBITDA loss and ended with $15.2 million of cash against $18.4 million of inventory, leaving limited room for repeated execution misses.
The former largest customer is explicitly not expected to purchase units in the second half, creating a material replacement burden.
Gross margin declined to 34.8% from 39.7%, and Fair Deal placements consume resources before utilization produces meaningful revenue.
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
From latest 10-K · 2026-03-04
- Net Margin Sharply Negative
Red flags
- Net Margin Sharply Negative — Net margin -28.1%